

1-5 (Canceled)

6. (Currently amended) A pharmaceutical composition for treating or ameliorating type 1 diabetes comprising a hormonally inactive insulin analogue in an amount effective for said treating or ameliorating, wherein said analogue is selected from the group consisting of desA1 human insulin, des(A1-A2) human insulin, des(A1-A3) human insulin, desA21 human insulin, des(B1-B5) human insulin, des(B1-B6) human insulin, des(B24-B30) human insulin, des(B25-B30) human insulin, Gly^{A2} human insulin, Ala^{A2} human insulin, Nle^{A2} human insulin, Thr^{A2} human insulin, Pro^{A2} human insulin, D-allo Ile^{A2} human insulin, Nva^{A3} human insulin, Nle^{A3} human insulin, Leu^{A3} human insulin, Val^{A2}, Ile^{A3} human insulin, Abu^{A2}, Abu^{A3} human insulin, Gly^{A2}, Gly^{A3} human insulin, D-Cys^{A6} human insulin, D-Cys^{A6}, D-Cys^{A11} human insulin, Ser^{A6}, Ser^{A11}, des(A8-A10) human insulin, D-Cys^{A7} human insulin, D-Cys^{A11} human insulin, Leu^{A19} human insulin, Gly^{B6} human insulin, Glu^{B12} human insulin, Asn^{B12} human insulin, Phe^{B12} human insulin, D-Ala^{B12} human insulin, and Asp^{B25} human insulin.

7. (Canceled)

8. (Currently amended) The pharmaceutical composition of claim 6, wherein the ~~*in vitro*~~ activity of the insulin analogue in an *in vitro* fat cell or receptor binding assay is less than 7% of the activity of human insulin.

9. (Original) The pharmaceutical composition of claim 6, wherein the insulin analogue is Asp^{B25} human insulin.

11. (Withdrawn) The pharmaceutical composition of claim 6, wherein the insulin analogue is in the form of hexameric complexes in a solution.